PRP Therapy for Alopecia After Breast Cancer Treatment

Age: 18 - 65

Sex: Any

Trial Phase: Phase < 1

Sponsor: Memorial Sloan Kettering Cancer Center

Must not be taking: Anticoagulants, NSAIDs

Disqualifiers: Pregnancy, Hair transplantation, Scalp conditions, Hematologic disorders, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 3

Duration: 12 weeks

30 Participants Needed

Trial Summary

What is the purpose of this trial?

Participants who enroll in this study will undergo the platelet-rich plasma (PRP) study treatment. Participants will have a sample of blood collected and the platelets will be separated and then injected into half of the participants' scalp every 4 weeks for 12 weeks.

Will I have to stop taking my current medications?

You may need to stop certain medications before joining the trial. If you've used topical minoxidil or spironolactone for hair loss, you'll need a 3-month break before starting. Also, if you're taking aspirin, NSAIDs, or fish-oil supplements, you'll need to stop them 7 days before treatment.

Is PRP therapy generally safe for humans?

Research on PRP therapy, especially for hair loss conditions like androgenic alopecia, shows it has beneficial effects without major adverse reactions, indicating it is generally safe for humans. ^{1 2 3 4 5}

How is PRP treatment different from other treatments for alopecia after breast cancer?

PRP treatment is unique because it uses a concentration of platelets from the patient's own blood to promote hair growth, making it a natural and minimally invasive option compared to other treatments. It is administered through injections and is considered safe and effective for various types of hair loss, including those not typically addressed by standard treatments. ^{1 2 3 6 7}

Research Team

Anthony Rossi, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for women over 18 with hair loss after breast cancer treatment, who haven't used endocrine therapy in the last 6 months or certain alopecia treatments without a 3-month break. It's not for those pregnant, breastfeeding, with scalp conditions, past hair transplants, taking anticoagulants (unless stopped a week before), or on fish oil/NSAIDs without pausing them.

Inclusion Criteria

I am taking a medication called leuprolide.

I have hair loss due to hormone therapy for breast cancer.

I have hair loss from breast cancer treatment and haven't used hormone therapy in the last 6 months.

Exclusion Criteria

I have an active skin condition on my scalp or a history of scalp skin cancer.

I can stop taking Aspirin, NSAIDs, or fish-oil supplements 7 days before treatment starts.

I am currently taking blood thinner medication.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo platelet-rich plasma (PRP) treatment with injections into the scalp every 4 weeks

12 weeks

3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• PRP Treatment

Trial Overview The study tests PRP treatment where participants' own platelets are injected into their scalp to treat hair loss caused by cancer therapy. The process involves blood collection and platelet separation every four weeks for three months.

Participant Groups

Group I: Female Breast Cancer Pts Experimental Treatment 1 Intervention

Participants include female breast cancer patients who either receive endocrine therapy and suffer from endocrine induced alopecia or suffer from post chemotherapy induced alopecia.

PRP Treatment is already approved in United States, Canada, European Union for the following indications:

Approved in United States as Platelet-Rich Plasma Therapy for:

• None specifically approved for knee osteoarthritis; some preparations have FDA approval for other uses but are used off-label for OA

Approved in Canada as Platelet-Rich Plasma Therapy for:

• Not recommended in international OA treatment guidelines due to lack of high-quality evidence

Approved in European Union as Platelet-Rich Plasma Therapy for:

• Not specifically approved for knee osteoarthritis; used off-label in some clinics

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Findings from Research

Platelet-rich plasma (PRP) is derived from a patient's own blood and contains a high concentration of platelets, which can enhance tissue regeneration.

PRP has shown effectiveness in treating various types of hair loss, including androgenic alopecia and alopecia areata, expanding its use beyond orthopedic applications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Platelet Rich Plasma for the Treatment of Scarring Alopecia Due to Discoid Lupus Erythematosus. Polster, H., Kagha, K., Luke, J.[2022]

References

1. England pubmed.ncbi.nlm.nih.gov

Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial. [2023]

2. United States pubmed.ncbi.nlm.nih.gov

Platelet Rich Plasma for the Treatment of Scarring Alopecia Due to Discoid Lupus Erythematosus. [2022]

3. United States pubmed.ncbi.nlm.nih.gov

A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Efficacy of Activated 3X Platelet-Rich Plasma in the Treatment of Androgenic Alopecia. [2022]

5. India pubmed.ncbi.nlm.nih.gov

Efficacy of platelet-rich plasma in treatment of androgenic alopecia. [2022]

6. United States pubmed.ncbi.nlm.nih.gov

Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia. [2022]

7. United States pubmed.ncbi.nlm.nih.gov

Platelet-Rich Plasma in Alopecia areata: A Case Report With a Mini Review of Literature. [2023]